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OBJECTIVES 
 To investigate clinical and 
demographic factors influencing 
gentamicin pharmacokinetics in a 
large cohort of unselected newborns. 
 To derive optimal regimen to achieve 
optimal therapeutic targets of 8 mg/L 
for peak and under 1mg/L for trough 
concentrations. 
RESULTS 
 A total of 3039 gentamicin serum concentrations were collected in 994 preterm and 455 term newborns treated at 
the University Hospital Center of Lausanne between December 2006 and October 2011. 
 Nonlinear mixed effect modeling (NONMEM ®) was used to develop a population pharmacokinetic model 
describing gentamicin disposition in this population. 
 Continuous covariates were body weight (BW), gestational age (GA), postnatal age (PNA), postmenstrual age (PMA 
defined as the sum of PNA and GA). 
 Categorical covariates were sex, cotreatment with furosemide (FURO), dopamine (DOPA) and indometacin (INDO), 
presence of patent ductus arteriosous (PDA) and concomitant ventilation (invasive (IV) and non-invasive (NIV)). 
METHODS 
Data 
 Concentrations measured at peak 
and at about 12 hours after the last 
dose represent 42% and 40% of the 
measurements, respectively. Most 
measurements (86%) were performed 
after the first administration and only 
3% of concentrations were available 
beyond 72 hours of treatment.  
Structural  and error model 
 A two-compartment model best characterized gentamicin 
pharmacokinetics. Average clearance (CL) was 0.095 L/h 
(CV 25%), central volume of distribution (Vc) 0.960 L (CV 
18%), intercompartmental clearance (Q) 0.086 L/h and 
peripheral volume of distribution (Vp) 0.261 L.  
 A mixed error model was used to describe intra-patient 
variability, where additive and proportional residual error 
were 0.199 mg/L and 17% respectively. 
 A correlation of 87% was found between clearance and  
central volume of distribution. 
Covariate model 
 BW on CL and Vc (following allometric equations 
with a power of 0.75 and 1 respectively) was the 
covariate that markedly improved the description 
of the data. This factor explained 57% of the 
variability in CL and 76% in Vc.  
 Further covariates were GA and PNA on CL 
(increasing CL by 6% per week and 3.5% per 
day respectively) and GA on Vc (decreasing Vc 
by 1.5% per week). 
 Co-administration of dopamine reduced CL by 
10% and increased Vc by  10%.  
 CL was reduced by 32% in presence of 
furosemide. Although not significant, indometacin 
reduced CL by 12%. 
Simulation 
 Model based simulation confirms that 
preterm infants need higher dose, 
superior to 4 mg/kg, and extended 
interval dosage regimen to achieve 
adequate concentration. 
DISCUSSION-CONCLUSION 
 To our knowledge, this study is the largest population pharmacokinetic analysis of gentamicin in a cohort of unselected neonates. 
 Gentamicin shows a two-compartment kinetics in the newborns where size (represented by BW as a surrogate) and maturation (represented by GA and 
PNA) are the most important covariates influencing individual pharmacokinetic parameters. 
 Dopamine and furosemide were also found to have a relevant effect. Probably, dopamine is an indicator of bad general state associated with diminished 
clearance (cardiovascular instability, a diminished renal blood flow and increase of the vascular resistance).  
 Even if PMA predicts gentamicin clearance, separating the two distinct covariates GA and PNA  better fits the data than PMA alone.  
 The model will serve to elaborate a Bayesian tool for gentamicin dosage individualization in newborns (http://www.ezechiel.ch/). 
Gentamicin concentrations versus time plots with 
population prediction (solid line) and the 80% prediction 
interval (dotted lines) for a first dose. 
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Model equations 
Median C1h (mg/L) 6.15 (CI80%: 3.61-9.78) 
Median C12h (mg/L) 1.78 (CI80%: 0.74-3.07) 
Characteristics Value  
Dose (mg/kg) 2.9 (1.0-20.2) a 
BW (g) 2170 (440-5510)a 
GA (wk) 34.0 (24.2-42.1)a 
PNA (d) 1 (0-94) a 
PMA (wk) 34.4 (24.2-42.4) a 
Male 834 (57.5) b 
IV 301 (20.8) b 
NIV 861 (59.4) b 
PDA 153 (10.6) b  
Furosemide 5 (0.3) b 
Dopamine 136 (9.4) b 
Indometacin 27 (1.9) b 
a   median (range) 
b   count (%) 
Characteristics of the patients 
Parameters 
Population means 
Estimate SE(%) IIV(%) SE(%) 
θCL (L/h) 0.095 1 25 10
  
θBWCL 0.75 - 
θGACL 2.034 4 
θPNACL 0.036 20
  
θDOPACL -0.096 37
  
θFUROCL -0.318 43 
θVc (L)
  0.960 3  18 44 
θBWVc 1 - 
θGAVc -0.519 15
  
θDOPAVc 0.098 29 
θQ  (L/h)
  0.086 32  
θVp (L) 0.261 16
  
Correlation CL-Vc (%) 87 21 
Additive residual error 
(mg/L) 
0.199 17  
Proportional residual 
error (%) 
17 5  
Final population pharmacokinetic parameter estimates of 
gentamicin in neonates 
